DBV Technologies S.A. (DBVT)
$
10.83
-0.17 (-1.57%)
Key metrics
Financial statements
Free cash flow per share
-0.8816
Market cap
297 Million
Price to sales ratio
255.8062
Debt to equity
2.6126
Current ratio
0.7218
Income quality
0.7871
Average inventory
0
ROE
-2.6846
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
DBV Technologies S.A. is a clinical-stage biopharmaceutical company engaged in the research and development of epicutaneous immunotherapy products. Its lead product candidate, Viaskin Peanut, has successfully completed Phase III clinical trials for the treatment of peanut allergies in children aged 4 to 11, as well as in adolescents and adults. Additionally, the company is advancing Viaskin Milk, which is currently in Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA). Viaskin Egg is in the pre-clinical stage aimed at addressing hen's egg allergy, while the company is also developing a booster vaccine for Bordetella pertussis. Other early-stage research programs are focused on potential vaccines for respiratory syncytial virus, as well as treatments targeting Crohn's disease, celiac disease, and type I diabetes. DBV Technologies has formed a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test designed for diagnosing non-IgE mediated CMPA in infants and toddlers. The company's financial performance reflects a nuanced complexity; it earned an interest income of $2,726,000.00 showcasing its financial investments, while the gross profit ratio stands at -1.66 reflecting the efficiency of its production and sales operations. The EBITDA ratio is -43.30 highlighting the operational efficiency of the organization, and the diluted EPS is -$5.90 accounting for potential share dilution. Furthermore, the total costs and expenses for the company are -$120,740,000.00 reflecting its overall spending in the biopharmaceutical sector. In the context of its market presence, the stock of DBV Technologies is affordable at $10.83 making it suitable for budget-conscious investors. With an average trading volume of 66,015.00 the stock indicates moderate liquidity, allowing investors to engage with the company without excessive market impact. With a market capitalization of $296,238,879.00 DBV Technologies is classified as a small-cap player within its field. It serves as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth as it belongs to the Healthcare sector. This positioning underscores its importance and potential impact on advancements in biopharmaceutical research and development.
Is DBV Technologies S.A. (DBVT) a good investment?
Investing in DBV Technologies S.A. (DBVT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is DBV Technologies S.A. (DBVT)'s stock forecast?
Analysts predict DBV Technologies S.A. stock to fluctuate between $0.44 (low) and $12.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is DBV Technologies S.A.'s market capitalization?
As of 2025-07-10, DBV Technologies S.A.'s market cap is $296,238,879, based on 27,343,697 outstanding shares.
How does DBV Technologies S.A. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., DBV Technologies S.A. has a Lower Market-Cap, indicating a difference in performance.
How can I buy DBV Technologies S.A. (DBVT) stock?
To buy DBV Technologies S.A. (DBVT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DBVT. Place an order (Market, Limit, etc.).
What is the best time to invest in DBV Technologies S.A.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has DBV Technologies S.A. stock ever split?
DBV Technologies S.A.'s last stock split was 1:5 on 2024-11-29.
How did DBV Technologies S.A. perform in the last earnings report?
Revenue: $2,568,000 | EPS: -$5.90 | Growth: 66.20%.
Where can I find DBV Technologies S.A.'s investor relations reports?
Visit https://www.dbv-technologies.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for DBV Technologies S.A.?
You can explore historical data from here
What is the all-time high and low for DBV Technologies S.A. stock?
All-time high: $68.80 (2021-04-30) | All-time low: $2.20 (2024-11-19).
What are the key trends affecting DBV Technologies S.A. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe.
globenewswire.com
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
globenewswire.com
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025.
zacks.com
Here is how DBV Technologies S.A. (DBVT) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
zacks.com
Does DBV Technologies S.A. (DBVT) have what it takes to be a top stock pick for momentum investors?
zacks.com
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
globenewswire.com
Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event.
zacks.com
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
globenewswire.com
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes from the unaudited financial statements examined by the Board of Directors on March 23 and published in the Company's press release dated March 24, 2025; The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the 2024 URD includes the following information: The Annual Financial Report; The Management Report (“rapport de gestion”); The Corporate Governance Report; The description of the Share Buyback Program.
marketwatch.com
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
See all news
